Cilostazol Cilostazol RSS feedThis is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.

This page shows you the latest news and research items in this category.

Effects of cilostazol on fracture healing: an experimental study.
CONCLUSION: In the long term, cilostazol did not show any positive effect on fracture healing clinically, radiologically or histologically. PMID: 26854057 [PubMed - in process] (Source: Acta Orthopaedica et Traumatologica Turcica)
Source: Acta Orthopaedica et Traumatologica Turcica - February 9, 2016 Category: Orthopaedics Authors: Alıç T, Çıraklı A, Şahin Y, Tomak Y Tags: Acta Orthop Traumatol Turc Source Type: research

Nanosuspension formulations of poorly water‐soluble compounds for intravenous administration in exploratory toxicity studies: in vitro and in vivo evaluation
This study was conducted to investigate the use of a nanosuspension for intravenous injection into dogs to increase exposure without toxic additives for preclinical studies in the discovery stage. Nanosuspensions were prepared with a mixer mill and zirconia beads with a vehicle of 2% (w/v) poloxamer 338, which was confirmed to lead to no histamine release in dogs. Sterilized nanosuspensions of poorly water‐soluble compounds, cilostazol (Cil), spironolactone (Spi) and probucol (Pro), at 10 mg ml−1 were obtained by milling for 30 min, followed by autoclaving for 20 min at 121 °C and milling for 30 min (mill–autoclave...
Source: Journal of Applied Toxicology - February 5, 2016 Category: Toxicology Authors: Hisako Fujimura, Takao Komasaka, Taizo Tomari, Yasunori Kitano, Kouji Takekawa Tags: Research article Source Type: research

Comparative Efficacy and Safety of Nine Anti-Platelet Therapies for Patients with Ischemic Stroke or Transient Ischemic Attack: a Mixed Treatment Comparisons
Abstract Anti-platelet treatments, an effective anti-thrombotic therapy, are widely used in non-cardioembolic ischemic stroke or transient ischemic attack (TIA), including aspirin, cilostazol, clopidogrel, and other mono or dual therapies, while the optimal choice remains uncertain. All the literatures of 38 eligible randomized control trials were searched in PubMed, Embase, and China National Knowledge Internet (CNKI) without language limitation. And, nine anti-platelet therapies were assessed, including aspirin, clopidogrel, cilostazol, ticlopidine, triflusal, terutroban, sarpogrelate, dipyridamole plus aspirin,...
Source: Molecular Neurobiology - February 5, 2016 Category: Neurology Source Type: research

Cilostazol Improves Developmental Competence of Pig Oocytes by Increasing Intraoocyte Cyclic Adenosine Monophosphate Level and Delaying Meiotic Resumption
This study was conducted to determine the effects of CLZ treatment during in vitro maturation (IVM) on developmental competence of pig oocytes. Immature oocytes were exposed to 0 (control), 0.5, 2 and 4 μm CLZ during the first 22 h of IVM. Nuclear maturation, intraoocyte glutathione content and embryo cleavage after parthenogenesis (PA) and somatic cell nuclear transfer (SCNT) were not influenced by CLZ at any concentrations. However, 4 μm CLZ significantly (p < 0.05) improved blastocyst formation after PA (52.1% vs 38.7–46.0%) and SCNT relative to other concentrations (40.8% vs 25.0–30.7%). The mean cell nu...
Source: Reproduction in Domestic Animals - February 2, 2016 Category: Reproduction Medicine Authors: F Elahi, H Lee, Y Lee, B Park, J Lee, S‐H Hyun, E Lee Tags: Original Article Source Type: research

Pharmacological treatment for Buerger's disease.
CONCLUSIONS: Moderate quality evidence suggests that intravenous iloprost (prostacyclin analogue) is more effective than aspirin for eradicating rest pain and healing ischaemic ulcers in Buerger's disease, but oral iloprost is not more effective than placebo. Verylow and low quality evidence suggests there is no difference between prostacyclin (iloprost and clinprost) and the prostaglandin analogue alprostadil for healing ulcers and relieving pain respectively in severe Buerger's disease. Very-low quality evidence suggests there is no difference in pain scores and amputation rates between folic acid and placebo, in people ...
Source: Cochrane Database of Systematic Reviews - February 1, 2016 Category: Journals (General) Authors: Cacione DG, Baptista-Silva JC, Macedo CR Tags: Cochrane Database Syst Rev Source Type: research

Cellular and Ionic Mechanisms Underlying Effects of Cilostazol, Milrinone and Isoproterenol to Suppress Arrhythmogenesis in an Experimental Model of Early Repolarization Syndrome
Early Repolarization Syndrome (ERS) is associated with polymorphic ventricular tachycardia (PVT) and fibrillation (VF), leading to sudden cardiac death. (Source: Heart Rhythm)
Source: Heart Rhythm - January 25, 2016 Category: Cardiology Authors: Bence Patocskai, Hector Barajas-Martinez, Dan Hu, Zsolt Gurabi, István Koncz, Charles Antzelevitch Source Type: research

Characterization of White Matter Injury in a Rat Model of Chronic Cerebral Hypoperfusion [Brief Reports]
Conclusions— White matter injury induced by chronic cerebral hypoperfusion can be characterized by disintegration of diverse white matter components. Cilostazol might be a therapeutic strategy against white matter disintegration in patients with vascular dementia. (Source: Stroke)
Source: Stroke - January 25, 2016 Category: Neurology Authors: Choi, B.-R., Kim, D.-H., Back, D. B., Kang, C. H., Moon, W.-J., Han, J.-S., Choi, D.-H., Kwon, K. J., Shin, C. Y., Kim, B.-R., Lee, J., Han, S.-H., Kim, H. Y. Tags: Animal Models of Human Disease, Basic Science Research, Ischemia, Cerebrovascular Disease/Stroke Brief Reports Source Type: research

A systematic review and meta-analysis of adjunctive therapies in diabetic foot ulcers
Multiple adjunctive therapies have been proposed to accelerate wound healing in patients with diabetes and foot ulcers. The aim of this systematic review is to summarize the best available evidence supporting the use of hyperbaric oxygen therapy (HBOT), arterial pump devices, and pharmacologic agents (pentoxifylline, cilostazol, and iloprost) in this setting. (Source: Journal of Vascular Surgery)
Source: Journal of Vascular Surgery - January 21, 2016 Category: Surgery Authors: Tarig Elraiyah, Apostolos Tsapas, Gabriela Prutsky, Juan Pablo Domecq, Rim Hasan, Belal Firwana, Mohammed Nabhan, Larry Prokop, Anil Hingorani, Paul L. Claus, Lawrence W. Steinkraus, Mohammad Hassan Murad Source Type: research

Controversies in antiplatelet therapy in the secondary prevention of stroke
Publication date: Available online 19 January 2016 Source:European Geriatric Medicine Author(s): T. Adamek Recurrence of stroke has been estimated at 3–4% yearly after TIA or stroke. There is no clear agreement in choosing antiplatelet therapy at this time. Europeans, Americans and British guidelines have been different. Aspirin is still used in secondary prevention of ischemic stroke, because of the longest experience with the best-achieved results in different studies and low price. Other used drugs are a combination of aspirin and dipyridamole, P2Y12 receptor antagonists – clopidogrel, ticlopidine, prasugrel an...
Source: European Geriatric Medicine - January 20, 2016 Category: Geriatrics Source Type: research

Cilostazol attenuates gentamicin-induced nephrotoxicity in rats.
CONCLUSION: Cilostazol protected rats from gentamicin-induced nephrotoxicity possibly, in part through its antioxidant and anti-apoptotic activity. PMID: 26809659 [PubMed - as supplied by publisher] (Source: Experimental and Toxicologic Pathology)
Source: Experimental and Toxicologic Pathology - January 19, 2016 Category: Pathology Authors: Abdelsameea AA, Mohamed AM, Amer MG, Attia SM Tags: Exp Toxicol Pathol Source Type: research

Toward a pragmatic migraine model for drug testing: 1. Cilostazol in healthy volunteers
Conclusion Despite similarities with migraine headache, cilostazol-induced headache in healthy volunteers does not respond to sumatriptan. (Source: Cephalalgia)
Source: Cephalalgia - January 18, 2016 Category: Neurology Authors: Hansen, E. K., Guo, S., Ashina, M., Olesen, J. Tags: Original Articles Source Type: research

Induction of Angiogenesis by a Type III Phosphodiesterase Inhibitor, Cilostazol, Through Activation of Peroxisome Proliferator-Activated Receptor-γ and cAMP Pathways in Vascular Cells.
CONCLUSIONS: Our data suggest that the favorable effects of cilostazol on ischemic leg might be through the angiogenesis through the induction of HGF via peroxisome proliferator-activated receptor-γ and cAMP pathways. PMID: 26769045 [PubMed - as supplied by publisher] (Source: Arteriosclerosis, Thrombosis and Vascular Biology)
Source: Arteriosclerosis, Thrombosis and Vascular Biology - January 14, 2016 Category: Cardiology Authors: Sanada F, Kanbara Y, Taniyama Y, Otsu R, Carracedo M, Ikeda-Iwabu Y, Muratsu J, Sugimoto K, Yamamoto K, Rakugi H, Morishita R Tags: Arterioscler Thromb Vasc Biol Source Type: research

Cilostazol: an antiplatelet agent for the neurointerventionist?
Antiplatelet agents are essential for the successful management of patients undergoing a variety of neurointerventional procedures. The most commonly used anti-platelet agents are aspirin, clopidogrel and prasugrel. However, there exist an alternative class of anti-platelet agent that may prove useful for neurointerventionists. In particular a drug called cilostazol may have numerous added advantages above and beyond its antiplatelet effect that may be valuable for our patients. In this short review we aim to highlight some of these potential advantages. (Source: Journal of NeuroInterventional Surgery)
Source: Journal of NeuroInterventional Surgery - January 13, 2016 Category: Neurosurgery Authors: Bhogal, P., Brouwer, P. A., Makalanda, H. L. D. Tags: Clinical neurology Source Type: research

Addition of cilostazol to aspirin therapy for secondary prevention of cardiovascular and cerebrovascular disease in patients undergoing percutaneous coronary intervention: A randomized, open-label trial
Conclusions In patients who underwent coronary stent implantation, the addition of cilostazol to aspirin therapy was associated with lower rates of cardiovascular and cerebrovascular events at 2 years compared with aspirin monotherapy. (Source: American Heart Journal)
Source: American Heart Journal - January 12, 2016 Category: Cardiology Source Type: research

Anti-depressant effects of phosphodiesterase 3 inhibitor cilostazol in chronic mild stress-treated mice after ischemic stroke
Conclusions Our results suggest that phosphodiesterase 3 inhibitor cilostazol may have anti-depressant effects on post-stroke depression through inhibition of neurodegeneration in the primary lesion and secondary extrafocal sites and promotion of neurogenesis. These beneficial effects on post-stroke depression may be involved in activation of CREB/BDNF signaling. (Source: Psychopharmacology)
Source: Psychopharmacology - December 21, 2015 Category: Psychiatry Source Type: research

Comparative Fasting Bioavailability of 2 Cilostazol Formulations in Healthy Thai Volunteers: An Open-Label, Single-Dose, Randomized, 2-Way Crossover Study.
CONCLUSION: No significant difference in the analyzed pharmacokineticparameters was found between the twoformulations of 50 mg cilostazol tablets. Therefore, it can be concluded that these two cilostazol tablet formulations were considered bioequivalent. PMID: 26591403 [PubMed - indexed for MEDLINE] (Source: Journal of the Medical Association of Thailand = Chotmaihet thangphaet)
Source: Journal of the Medical Association of Thailand = Chotmaihet thangphaet - December 20, 2015 Category: Journals (General) Tags: J Med Assoc Thai Source Type: research

The Changes in Mean Platelet Volume after Using of Antiplatelet Drugs in Acute Ischemic Stroke: A Randomized Controlled Trial.
CONCLUSION: Every type of antiplatelets included in this study reduced MPV NIHSS, and mRS in acute non-cardioembolic stroke patients. Clopidogrel improved NIHSS the most. PMID: 26591394 [PubMed - indexed for MEDLINE] (Source: Journal of the Medical Association of Thailand = Chotmaihet thangphaet)
Source: Journal of the Medical Association of Thailand = Chotmaihet thangphaet - December 20, 2015 Category: Journals (General) Tags: J Med Assoc Thai Source Type: research

CILOSTAZOL Tablet [Avera McKennan Hospital]
Updated Date: Dec 18, 2015 EST (Source: DailyMed Drug Label Updates for the last seven days (since May 20, 2007 EST))
Source: DailyMed Drug Label Updates for the last seven days (since May 20, 2007 EST) - December 18, 2015 Category: Drugs & Pharmacology Source Type: news

Effect of oral cilostazol on acute neurological deterioration and outcome of noncardioembolic minor stroke
Conclusion In noncardioembolic stroke, combined antithrombotic therapy with early oral cilostazol in the acute phase appears to be associated with a good outcome in patients with progressive stroke. (Source: Journal of Clinical Gerontology and Geriatrics)
Source: Journal of Clinical Gerontology and Geriatrics - December 18, 2015 Category: Geriatrics Source Type: research

Beneficial cilostazol therapeutic effects in mdx dystrophic skeletal muscle.
In conclusion, the present results show that cilostazol has beneficial effects in dystrophic muscle. More research into the potential of cilostazol as a novel therapeutic agent for the treatment of dystrophinopathies is required. This article is protected by copyright. All rights reserved. PMID: 26639107 [PubMed - as supplied by publisher] (Source: Clinical and Experimental Pharmacology and Physiology)
Source: Clinical and Experimental Pharmacology and Physiology - December 7, 2015 Category: Drugs & Pharmacology Authors: Hermes TA, Macedo AB, Fogaça AR, Moraes LH, de Faria FM, Kido LA, Cagnon VH, Minatel E Tags: Clin Exp Pharmacol Physiol Source Type: research

Cilostazol and blood viscoelasticity in homozygous sickle cell disease.
Authors: Lester DA, Richards AA, Younger-Coleman NO, Pepple DJ PMID: 25562995 [PubMed - indexed for MEDLINE] (Source: British Journal of Biomedical Science)
Source: British Journal of Biomedical Science - December 2, 2015 Category: Laboratory Medicine Tags: Br J Biomed Sci Source Type: research

Two young stroke patients associated with regular intravenous immunoglobulin (IVIg) therapy
We recently experienced 2 young adult patients who developed ischemic stroke after regular intravenous immunoglobulin (IVIg) therapy for agammaglobulinemia with diagnosis of common variable immunodeficiency (CVID) in their childhood. Patient 1 was 26-year-old woman, who developed Wallenberg's syndrome 6days after the last IVIg therapy, but had no further stroke recurrence with cilostazol later. Patient 2 was 37-year-old man, who developed recurrent cerebral infarction in the territory of bilateral lenticulostriate branches like branch atheromatous disease (BAD) several days after the IVIg therapy. (Source: Journal of the N...
Source: Journal of the Neurological Sciences - December 2, 2015 Category: Neurology Authors: Yumiko Nakano, Takeshi Hayashi, Kentaro Deguchi, Kota Sato, Nozomi Hishikawa, Toru Yamashita, Yasuyuki Ohta, Yoshiki Takao, Tomohiro Morio, Koji Abe Source Type: research

It Is Not Mandatory to Use Triple Rather Than Dual Anti-Platelet Therapy After a Percutaneous Coronary Intervention With a Second-Generation Drug-Eluting Stent
Abstract: It has been shown that triple antiplatelet therapy with cilostazol results in better clinical outcomes than dual therapy in patients treated with a first-generation drug-eluting stent (DES); however, it is unclear whether triple antiplatelet therapy has a similar efficacy after the implantation of second-generation DES. In the COACT (Cath Olic medical center percutAneous Coronary in Tervention) registry, 1248 study subjects who underwent percutaneous coronary intervention with an everolimus- or zotarolimus-eluting stent (Endeavor, Xience V, or Promus) were analyzed. The patients were divided into 2 groups after p...
Source: Medicine - November 1, 2015 Category: Internal Medicine Tags: Observational Study Source Type: research

Cilostazol inhibits interleukin-1-induced ADAM17 expression through cAMP independent signaling in vascular smooth muscle cells.
Abstract Increased a disintegrin and metalloprotease 17 (ADAM17) expression in vascular smooth muscle cells (VSMC) is implicated in the development of cardiovascular diseases including atherosclerosis and hypertension. Although cilostazol, type phosphodiesterase (PDE?) inhibitor, has recently been found to inhibit VSMC proliferation, the mechanisms remain largely unclear. Here we hypothesized that cilostazol regulates the ADAM17 expression in VSMC. In cultured VSMC, interleukin (IL)-1α and IL-1β significantly increased ADAM17 expression. MEK inhibitor U0126, NF-κB inhibitor BAY-11-7085 and siRNA targeting p65/Re...
Source: Cell Biology International - October 30, 2015 Category: Cytology Authors: Takaguri A, Morimoto M, Imai SI, Satoh K Tags: Cell Biol Int Source Type: research

CILOSTAZOL Tablet [Eon Labs, Inc.]
Updated Date: Oct 28, 2015 EST (Source: DailyMed Drug Label Updates for the last seven days (since May 20, 2007 EST))
Source: DailyMed Drug Label Updates for the last seven days (since May 20, 2007 EST) - October 28, 2015 Category: Drugs & Pharmacology Source Type: news

Cilostazol blocks pregnancy in naturally cycling swine: An animal model
This study shows that CLZ is capable of producing a reversible non-steroidal contraceptive effect without adverse effects on the heart rate in pigs. The observed contraceptive effect of CLZ was at doses similar to those indicated to humans. This FDA approved agent, for treatment of patients with intermittent claudication, may have an additional therapeutic effect as a non-steroidal contraceptive agent. Cilostazol merits further evaluation in women. (Source: Life Sciences)
Source: Life Sciences - October 23, 2015 Category: Biology Source Type: research

Serum Uric Acid Is Associated with Cerebral White Matter Hyperintensities in Patients with Acute Lacunar Infarction
CONCLUSIONSThis study showed that serum UA was associated with cerebral WMH in patients with acute lacunar infarction. (Source: Journal of Neuroimaging)
Source: Journal of Neuroimaging - October 13, 2015 Category: Radiology Authors: Sang Won Han, Tae Jin Song, Cheryl D. Bushnell, Sung‐Soo Lee, Seo Hyun Kim, Jun Hong Lee, Gyu Sik Kim, Ok‐Joon Kim, Im‐Seok Koh, Jong Yun Lee, Seung‐Han Suk, Sung Ik Lee, Hyo Suk Nam, Kyung‐Yul Lee, Jae Hyeon Park Tags: Clinical Investigative Study Source Type: research

The pharmacokinetic and pharmacodynamic interaction of clopidogrel and cilostazol in relation to CYP2C19 and CYP3A5 genotypes
ConclusionsAdditive antiplatelet effect of cilostazol to clopidogrel is maximized in subjects with both CYP2C19PM and CYP3A5*3/*3 because of lack of change of clopidogrel thiol metabolite exposure in CYP3A5*3/*3 as well as the highest cilostazol IPA in CYP2C19 PM or CYP3A5*3/*3. This article is protected by copyright. All rights reserved. (Source: British Journal of Clinical Pharmacology)
Source: British Journal of Clinical Pharmacology - October 1, 2015 Category: Drugs & Pharmacology Authors: Ho‐Sook Kim, Younghae Lim, Minkyung Oh, Jong‐lyul Ghim, Eun‐Young Kim, Dong‐Hyun Kim, Jae‐Gook Shin Tags: Drug Interactions Source Type: research

Low-dose adjunctive cilostazol in patients with complex lesions undergoing percutaneous coronary intervention.
In conclusion, low-dose adjunctive cilostazol seems superior to dual antiplatelet therapy in reducing recurrent ischemic events in patients with complex coronary lesions and two groups have similar incidence of bleeding events. This article is protected by copyright. All rights reserved. PMID: 26414108 [PubMed - as supplied by publisher] (Source: Clinical and Experimental Pharmacology and Physiology)
Source: Clinical and Experimental Pharmacology and Physiology - September 28, 2015 Category: Drugs & Pharmacology Authors: Zheng XT, Chen KY, Liu T, Xu LX, Che JJ, Rha SW, Li GP Tags: Clin Exp Pharmacol Physiol Source Type: research

The Latest Information on Intracranial Atherosclerosis: Diagnosis and Treatment
Intracranial atherosclerotic stenosis (ICAS) is the most common cause of ischemic stroke in the world. ICAS is especially common in the Asian population accounting for 30-50% of all ischemic strokes. The risk of recurrent stroke in patients with symptomatic ICAS is the highest among the stroke subtypes. Two major factors associated with recurrent stroke are high degree (>70%) of stenosis and progression of ICAS. Transcranial Doppler ultrasound, CT angiography, MR angiography, and conventional catheter angiography are used for the diagnosis of ICAS. Today, high-resolution MRI can provide important information to improve the...
Source: Interventional Neurology - September 18, 2015 Category: Neurology Source Type: research

Effects of cilostazol on the pharmacokinetics of carvedilol after oral and intravenous administration in rats.
This study was designed to investigate the effects of cilostazol on the pharmacokinetics of carvedilol following oral or intravenous administration of carvedilol in rats. Clinically carvedilol and cilostazol can be prescribed for treatment of cardiovascular diseases. Carvedilol and cilostazol are all substrates of CYP2C9 enzymes. Carvedilol was administered orally or intravenously without or with oral administration of cilostazol to rats. The effects of cilostazol on cytochrome P450 (CYP) 2C9 activity and P-gp activity were also evaluated. Cilostazol inhibited CYP2C9 activity in a concentration-dependent manner with 50% in...
Source: Journal of Physiology and Pharmacology - September 11, 2015 Category: Drugs & Pharmacology Tags: J Physiol Pharmacol Source Type: research

Combination of Cilostazol and L-Carnitine Improves Walking Performance in Peripheral Arterial Disease Model Rats
This study also revealed that cilostazol promotes angiogenesis, and L-carnitine additively contributes to functional improvement via a non-angiogenic mechanism.Pharmacology 2015;96:210-216 (Source: Pharmacology)
Source: Pharmacology - September 1, 2015 Category: Drugs & Pharmacology Source Type: research

Long-term clinical efficacy and safety of adding cilostazol to dual antiplatelet therapy after drug-eluting stent implantation in coronary arteries: A meta-analysis of randomized controlled trials
To assess the long-term clinical efficacy and safety of adding cilostazol (TAT) to conventional dual antiplatelet therapy (DAT) for patients undergoing drug-eluting stent (DES) implantation in coronary arteries. (Source: Thrombosis Research)
Source: Thrombosis Research - August 27, 2015 Category: Hematology Authors: Yandun Zou, Chunling Hu, Wenhui Ye, Limei Fan, Likun Xu, Aidong Zhang Tags: Full Length Article Source Type: research

Statin-Induced Cardioprotection Against Ischemia-Reperfusion Injury: Potential Drug-Drug Interactions. Lesson to be Learnt by Translating Results from Animal Models to the Clinical Settings
Abstract Numerous interventions have been shown to limit myocardial infarct size in animal models; however, most of these interventions have failed to have a significant effect in clinical trials. One potential explanation for the lack of efficacy in the clinical setting is that in bench models, a single intervention is studied without the background of other interventions or modalities. This is in contrast to the clinical setting in which new medications are added to the “standard of care” treatment that by now includes a growing number of medications. Drug-drug interaction may lead to alteration, dampening, ...
Source: Cardiovascular Drugs and Therapy - August 25, 2015 Category: Cardiology Source Type: research

Long-Term Antiplatelet Mono- and Dual Therapies After Ischemic Stroke or Transient Ischemic Attack: Network Meta-Analysis [Stroke]
Conclusions Long-term monotherapy was a better choice than long-term dual therapy, and cilostazol had the best risk–benefit profile for long-term secondary prevention after stroke or transient ischemic attack. More randomized controlled trials in non–East Asian patients are needed to determine whether long-term use of cilostazol is the best option for the prevention of recurrent stroke. (Source: JAHA:Journal of the American Heart Association)
Source: JAHA:Journal of the American Heart Association - August 24, 2015 Category: Cardiology Authors: Xie, W., Zheng, F., Zhong, B., Song, X. Tags: Stroke Source Type: research

Suppression of RANKL-induced osteoclast differentiation by cilostazol via SIRT1-induced RANK inhibition
In conclusion, cilostazol activates SIRT1, which suppresses the nuclear translocation of PU.1, and thus, inhibits RANKL-stimulated RANK expression and causes anti-osteoclast formation in BMMs in vitro and in their murine model of CIA. (Source: Biochimica et Biophysica Acta (BBA) Molecular Basis of Disease)
Source: Biochimica et Biophysica Acta (BBA) Molecular Basis of Disease - August 13, 2015 Category: Molecular Biology Source Type: research

Effect of Cilostazol Following Endovascular Intervention for Peripheral Artery Disease
Efficacy of endovascular therapy (EVT) with nitinol stents for femoropopliteal (FP) lesions is limited by restenosis. Oral cilostazol reduces angiographic restenosis rate; however, treatment duration remains unclear. In a retrospective analysis of a multicenter database of 3471 consecutive limbs in 2737 patients (mean age: 72 ± 9 years; 61% diabetic; and 26% on regular dialysis) undergoing EVT for FP lesions between January 2004 and December 2011, we compared Kaplan-Meier estimated primary patency after EVT followed or not by cilostazol treatment. We used Cox hazard regression analysis to assess temporal association...
Source: Angiology - August 12, 2015 Category: Cardiology Authors: Nanto, K., Iida, O., Takahara, M., Soga, Y., Suzuki, K., Hirano, K., Kawasaki, D., Shintani, Y., Suematsu, N., Yamaoka, T., Uematsu, M. Tags: Peripheral Artery Disease Source Type: research

Combined use of probucol and cilostazol with atorvastatin attenuates atherosclerosis in moderately hypercholesterolemic rabbits
Conclusions: These data demonstrated that combined drug treatment exhibits potent athero-protective effects via pleiotropic functions, such as anti-inflammatory and anti-oxidative stress, which is independent of the lipid-lowering effect. (Source: Lipids in Health and Disease)
Source: Lipids in Health and Disease - July 29, 2015 Category: Lipidology Authors: Yanli WangLiang BaiYan LinYulong ChenHua GuanNinghong ZhuYafeng LiShoucui GaoLijing SunSihai ZhaoJianglin FanEnqi Liu Source Type: research

Increased expression of ATP-binding cassette transporter A1 (ABCA1) as a possible mechanism for the protective effect of cilostazol against hepatic steatosis
Cilostazol, a phosphodiesterase 3, has been widely used in patients with arterial disease and is known to have additional beneficial effects on dyslipidemia. However, the effect of cilostazol on hepatic steatosis has not been fully elucidated. We investigated the effect of cilostazol on hepatic ABCA1 expression and hepatic steatosis in diet-induced obesity mice model. (Source: Metabolism - Clinical and Experimental)
Source: Metabolism - Clinical and Experimental - July 24, 2015 Category: Biomedical Science Authors: Byung Hun Jeon, Yong-ho Lee, Mi Ra Yun, Soo Hyun Kim, Byung Wan Lee, Eun Seok Kang, Hyun Chul Lee, Bong-Soo Cha Source Type: research

Intimal exfoliation Following Abnormal Circular Proliferation as a Cause for Acute Coronary Syndrome in a Patient with Polycythemia Vera
A 78-year-old female with a history of polycythemia vera (PV) was admitted due to sudden severe chest pain at rest. She had been treated with 500mg/day of hydroxycarbamide for PV (platelet counts ranging from 480,000 to 600,000/μl, leukocyte counts ranging from 14,500 to 18,000/μl, and hematocrit levels ranging from 37 to 42 %), and 100mg/day of cilostazol for previous cerebral transient ischemia attack. Physical examination revealed no specific findings except splenomegaly. Anterior ST-segment elevation myocardial infarction (STEMI) was diagnosed by electrocardiography. (Source: International Journal of Cardiology)
Source: International Journal of Cardiology - July 19, 2015 Category: Cardiology Authors: Tsuyoshi Nishiguchi, Atsushi Tanaka, Takashi Yamano, Takashi Kubo, Takashi Akasaka Source Type: research

Protective effect of cilostazol on doxorubicin-induced cardiomyopathy in mice.
Abstract Doxorubicin (Dox) is an effective anti-cancer drug, but its use is limited due to the adverse effect by inducing the irreversible dilated cardiomyopathy. Cilostazol (Cilo), a potent phosphodiesterase III inhibitor, has been reported to have an anti-inflammatory effect. Here, we investigated whether Cilo has a protective effect on Dox-induced cardiomyopathy (DIC). The mice were randomly divided into four groups: saline-control, Dox (15mg/kg), Dox (15mg/kg) plus Cilo (50mg/kg), and Cilo (50mg/kg). As results, the co-administration of Dox and Cilo significantly enhanced the left ventricular systolic function ...
Source: Free Radical Biology and Medicine - July 18, 2015 Category: Biology Authors: Sin Koh J, Yi CO, Won Heo R, Ahn JW, Rang Park J, Eun Lee J, Kim JH, Hwang JY, Seob Roh G Tags: Free Radic Biol Med Source Type: research

Cilostazol, Not Aspirin, Prevents Stenosis of Bioresorbable Vascular Grafts in a Venous Model.
CONCLUSIONS: Cilostazol prevents stenosis of bioresorbable vascular graft in a mouse inferior vena cava implantation model up to 24 weeks and is accompanied by reduction of smooth muscle cell proliferation and acute inflammation. PMID: 26183618 [PubMed - as supplied by publisher] (Source: Arteriosclerosis, Thrombosis and Vascular Biology)
Source: Arteriosclerosis, Thrombosis and Vascular Biology - July 16, 2015 Category: Cardiology Authors: Tara S, Kurobe H, de Dios Ruiz Rosado J, Best CA, Shoji T, Mahler N, Yi T, Lee YU, Sugiura T, Hibino N, Partida-Sanchez S, Breuer CK, Shinoka T Tags: Arterioscler Thromb Vasc Biol Source Type: research

New therapeutic effects of cilostazol in patients with ischemic disorders.
The objective of the present review is to analyze the existing data about the therapeutic effects of CIL, with the purpose of providing practical indications about this topic for the management of subjects affected by ischemic disorders. PMID: 26156267 [PubMed - in process] (Source: Current Vascular Pharmacology)
Source: Current Vascular Pharmacology - July 11, 2015 Category: Drugs & Pharmacology Authors: Biscetti F, Ferraccioli G, Flex A Tags: Curr Vasc Pharmacol Source Type: research

Understanding the role of antioxidant therapy for intermittent claudication; Good, bad, or both?
Abstract Peripheral arterial disease (PAD) is a global health issue, affecting 202 million people worldwide. The most common symptom of PAD is intermittent claudication (IC), which is associated with increased risk of cardiovascular morbidity and mortality, and thus is an area where new therapies are urgently needed. Currently the only FDA-approved medications for treating PAD-associated walking impairment are pentoxifylline and cilostazol. However, these agents have been shown to produce only minimal improvement in maximal treadmill walking distance. Much evidence exists for a role of oxidant stress and inflammati...
Source: American Journal of Physiology. Heart and Circulatory Physiology - July 10, 2015 Category: Physiology Authors: Miller SJ, Unthank JL Tags: Am J Physiol Heart Circ Physiol Source Type: research

Cilostazol attenuates murine hepatic ischemia and reperfusion injury via heme oxygenase-dependent activation of mitochondrial biogenesis
Hepatic ischemia-reperfusion (I/R) can cause hepatocellular injury associated with the inflammatory response and mitochondrial dysfunction. We studied the protective effects of the phosphodiesterase inhibitor cilostazol in hepatic I/R and the roles of mitochondria and the Nrf2/heme oxygenase-1 (HO-1) system. Wild-type, Hmox1–/–, or Nrf2–/– mice were subjected to hepatic I/R in the absence or presence of cilostazol followed by measurements of liver injury. Primary hepatocytes were subjected to cilostazol with the HO-1 inhibitor ZnPP, or Nrf2-specific siRNA, followed by assessment of mitochondrial bio...
Source: AJP: Gastrointestinal and Liver Physiology - July 1, 2015 Category: Gastroenterology Authors: Joe, Y., Zheng, M., Kim, H. J., Uddin, M. J., Kim, S.-K., Chen, Y., Park, J., Cho, G. J., Ryter, S. W., Chung, H. T. Tags: LIVER AND BILIARY TRACT Source Type: research

Stimulation of angiogenesis by cilostazol accelerates fracture healing in mice
This article is protected by copyright. All rights reserved (Source: Journal of Orthopaedic Research)
Source: Journal of Orthopaedic Research - July 1, 2015 Category: Orthopaedics Authors: Steven C. Herath, Thorsten Lion, Moritz Klein, David Stenger, Claudia Scheuer, Jörg H. Holstein, Philipp Mörsdorf, Mika F.R. Rollmann, Tim Pohlemann, Michael D. Menger, Tina Histing Tags: Research Article Source Type: research

Triple versus dual antiplatelet therapy after percutaneous coronary intervention for coronary bifurcation lesions: results from the COBIS (COronary BIfurcation Stent) II Registry
Abstract The efficacy and safety of adding cilostazol to aspirin plus clopidogrel (triple antiplatelet therapy, TAPT) have not been fully evaluated in complex percutaneous coronary intervention (PCI). We sought to investigate whether TAPT after PCI for bifurcation lesions improves long-term clinical outcomes. Consecutive patients undergoing PCI for bifurcation lesions were enrolled from 18 centers in Korea between 2003 and 2009. We compared target vessel failure (TVF), defined as a composite of cardiac death, myocardial infarction (MI), and target vessel revascularization (TVR), among 675 patients who received TA...
Source: Heart and Vessels - July 1, 2015 Category: Cardiology Source Type: research

Efficacy of cilostazol for the treatment of Raynaud’s phenomenon in systemic sclerosis patients
Abstract Cilostazol is a selective inhibitor of phosphodiesterase-III with antiplatelet, antithrombotic and vasodilating properties. The aim of our study was to evaluate the effect of the drug on vasculopathy and Raynaud’s phenomenon (RP), in a series of patients with systemic sclerosis (SSc), before and after cilostazol treatment. Twenty-one consecutive SSc patients with moderate or severe RP were enrolled in an open-label study. Cilostazol was administered at the dose of 100 mg twice a day, for 12 months. Evaluations included: daily RP attack diary documenting the frequency and duration of RP episodes, H...
Source: Clinical and Experimental Medicine - June 19, 2015 Category: Research Source Type: research

Can crystal engineering be as beneficial as micronisation and overcome its pitfalls?: A case study with cilostazol
In conclusion, crystal engineering by habit modification show potential for dissolution enhancement with an added advantage of improved flow properties over micronization technique, for poorly soluble drugs like cilostazol. Graphical abstract (Source: International Journal of Pharmaceutics)
Source: International Journal of Pharmaceutics - June 18, 2015 Category: Drugs & Pharmacology Source Type: research